AMLN

Banking on Buyouts in Biotech: Is It Smart?

Unless you really understand medicine, it's a very risky game. The chances of a little company scoring big and getting bought out are usually slim.

9 Biotech Buyout Players to Watch

The deal between Human Genome Sciences and GlaxoSmithKline is just the most recent of big pharma buyouts -- and these biotech players could be next.

M&A: Where the Hotspots Are

Both the number of deals and their value are down, but there's strong signs of life if you know where to look. Here's a guide to where the action is.

Manufacturing Woes Stop the Mo: Monday’s IP Market Recap

Markets reacted to a disappointing manufacturing report, starting out in negative territory before coming back for slight gains in the S&P and Nasdaq.

Should I Buy Bristol-Myers Squibb? 3 Pros, 3 Cons

Its deal to buy diabetes-drug maker Amylin will help, given that market's potential. Still, patent expirations loom large and won't be easily overcome.

Cue the Biotech M&A Attack!

A rush of buyout activity in biotechs like Human Genome and Illumina could produce more frenzied M&A deals down the road.

Q2: Second Verse, Just Like the First — Monday’s IP Market Recap

Second-quarter trading picks up where Q1 left off -- by advancing smartly on the first day of trading.

Here Comes a Bidding War for Amylin

Approval of its diabetes drug has Big Pharma banging on its door, with Bristol-Myers Squibb already said to have offered $3.5 billion, or $22 per share.

Amylin Perks Up on Rejection — Wednesday’s IP Market Recap

A spurned bid from Bristol-Myers Squibb sends AMLN up 54% on speculation that other offers will roll in.

‘Spam’ Linked to Diabetes in Native Americans

A new study raises questions about processed meat intake among Native Americans living on reservations and the development of diabetes.